<DOC>
	<DOCNO>NCT01695408</DOCNO>
	<brief_summary>Idiopathic pulmonary fibrosis ( IPF ) , manifestation chronic progressive fibrosing interstitial pneumonia , ia rare disease . Current treatment option limit , mean survival time newly diagnose ( mostly elderly ) patient 2-3 year . As Europe data limit characteristic management patient , INSIGHTS-IPF initiate new registry document newly diagnose ( incident ) prevalent patient confirm IPF diagnosis prospectively.The registry contribute optimization management IPF patient long term .</brief_summary>
	<brief_title>Investigating Significant Health Trends Idiopathic Pulmonary Fibrosis</brief_title>
	<detailed_description>INSIGHTS-IPF report current comprehensive data Idiopathic Pulmonary Fibrosis ( IPF ) long-term . Baseline ( cross-sectional part ) : Description characteristic IPF patient term - key ( socio- ) demographic data - IPF risk factor , comorbidities - method use IPF diagnosis - IPF disease severity manifestation ( include lung function , cardiopulmonary exercise test and/or exercise capacity available , laboratory value , biomarkers ) - IPF treatment ( detailed information prescribe drug dos ; non-pharmacological treatment ; list score lung transplantation ) - assessment patient-related outcome ( PRO ) quality life Follow-up ( prospectively least 2 year inclusion ) : - Clinical course IPF ( e.g . term symptom , lung function , exercise capacity available ) - Documentation treatment pathway ( switch/add-on/discontinuation medication ) , non-pharmacological treatment ( e.g . start long term oxygen therapy ; new listing lung transplantation ) Outcomes/events ( acute respiratory worsening , exacerbation , hospitalisation due cause due IPF , complication , survival ) - Patient-related outcome quality life , assess year ( comparison baseline ) - Resource use pharmacoeconomic analysis .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>At least 18 year age Written inform consent participation registry Newly diagnose ( incident ) know ( prevalent ) IPF ( base diagnosis treat physician )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Drug Treatment</keyword>
	<keyword>Treatment pathway</keyword>
	<keyword>Clinical routine</keyword>
	<keyword>Registry</keyword>
	<keyword>Outcomes</keyword>
	<keyword>Survival</keyword>
	<keyword>Patient-related outcome</keyword>
	<keyword>Quality life</keyword>
	<keyword>Steroids</keyword>
	<keyword>Azathioprine</keyword>
	<keyword>N-Acetylcysteine</keyword>
	<keyword>Pirfenidone</keyword>
	<keyword>Tyrosine kinase inhibitor</keyword>
	<keyword>Nintedanib</keyword>
	<keyword>multicenter</keyword>
	<keyword>Germany</keyword>
	<keyword>Safety</keyword>
	<keyword>Adverse event</keyword>
</DOC>